BIO-CANDESARTAN TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

CANDESARTAN CILEXETIL

Verfügbar ab:

BIOMED PHARMA

ATC-Code:

C09CA06

INN (Internationale Bezeichnung):

CANDESARTAN

Dosierung:

32MG

Darreichungsform:

TABLET

Zusammensetzung:

CANDESARTAN CILEXETIL 32MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100

Verschreibungstyp:

Prescription

Therapiebereich:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0135220004; AHFS:

Berechtigungsstatus:

CANCELLED PRE MARKET

Berechtigungsdatum:

2022-07-19

Fachinformation

_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35 _
_ _
PRODUCT MONOGRAPH
PR
BIO-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
BIOMED PHARMA
DATE OF PREPARATION:
5950, Côte de Liesse, Suite 100
June 15, 2016
Ville Mont-Royal
Québec H4T 1E2
SUBMISSION CONTROL #: 194909
_Bio-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35 _
_ _
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................................
4
ADVERSE REACTIONS
...........................................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................................
16
OVERDOSAGE
.......................................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
19
STORAGE AND STABILITY
.................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................................
22